MDB Capital (MDBH) & Its Peers Financial Review

Institutional and Insider Ownership

0.4% of MDB Capital shares are owned by institutional investors. Comparatively, 33.9% of shares of all “Nondepository credit institutions” companies are owned by institutional investors. 55.5% of MDB Capital shares are owned by insiders. Comparatively, 21.6% of shares of all “Nondepository credit institutions” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

MDB Capital has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, MDB Capital’s peers have a beta of 5.17, suggesting that their average share price is 417% more volatile than the S&P 500.

Valuation and Earnings

This table compares MDB Capital and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MDB Capital	$5.99 million	-$6.97 million	-2.37
MDB Capital Competitors	$2.74 billion	$383.60 million	24.14

MDB Capital’s peers have higher revenue and earnings than MDB Capital. MDB Capital is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares MDB Capital and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MDB Capital	N/A	-56.19%	-48.57%
MDB Capital Competitors	-61.40%	-71.73%	-3.72%

Summary

MDB Capital peers beat MDB Capital on 6 of the 9 factors compared.

MDB Capital Company Profile

MDB Capital Holdings, LLC, through its subsidiaries, primarily operates as a broker-dealer. The company operates through two segments, Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service segment operates as a full-service broker dealer that focuses on conducting private and public securities offerings, as well as providing research services for investment banking due diligence. The Technology Development segment engages in the synthetic biology technology development business. The company was founded in 1997 and is based in Addison, Texas.